These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25273975)

  • 1. Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.
    Pradelli J; Risso K; de Salvador FG; Cua E; Ruimy R; Roger PM
    Eur J Clin Microbiol Infect Dis; 2015 Mar; 34(3):511-8. PubMed ID: 25273975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
    Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia.
    Batard E; Lecadet N; Goffinet N; Hardouin JB; ; Lepelletier D; Potel G; Montassier E
    Infection; 2015 Dec; 43(6):681-9. PubMed ID: 25998004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-acquired pneumonia team decreases length of stay in hospitalized, low-risk patients with pneumonia.
    Marcos PJ; Restrepo MI; Sanjuàn P; Ferreira-Gonzalez L; Verea-Hernando H
    Hosp Pract (1995); 2013 Aug; 41(3):7-14. PubMed ID: 23948616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia.
    Chalmers JD; Singanayagam A; Akram AR; Choudhury G; Mandal P; Hill AT
    J Antimicrob Chemother; 2011 Feb; 66(2):416-23. PubMed ID: 21081545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals.
    Marras TK; Jamieson L; Chan CK
    Can Respir J; 2004 Mar; 11(2):131-7. PubMed ID: 15045044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
    Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
    Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
    Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
    J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia.
    Queen MA; Myers AL; Hall M; Shah SS; Williams DJ; Auger KA; Jerardi KE; Statile AM; Tieder JS
    Pediatrics; 2014 Jan; 133(1):e23-9. PubMed ID: 24324001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
    Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
    Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia.
    Belforti RK; Lagu T; Haessler S; Lindenauer PK; Pekow PS; Priya A; Zilberberg MD; Skiest D; Higgins TL; Stefan MS; Rothberg MB
    Clin Infect Dis; 2016 Jul; 63(1):1-9. PubMed ID: 27048748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
    Rahmel T; Asmussen S; Karlik J; Steinmann J; Adamzik M; Peters J
    BMC Anesthesiol; 2017 Jun; 17(1):78. PubMed ID: 28615012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
    Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
    Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from intravenous to oral antibiotics in hospitalized patients with community-acquired pneumonia: A real-world analysis 2010-2018.
    Kimura T; Ito M; Onozawa S
    J Infect Chemother; 2020 Jul; 26(7):706-714. PubMed ID: 32284180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.